These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 27312020)

  • 21. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
    Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
    J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
    Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [PCSK9 inhibitors: new treatment to lower cholesterol].
    Gencer B; Rodondi N; Mach F
    Rev Med Suisse; 2016 Mar; 12(508):440-2, 444. PubMed ID: 27089600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: A retrospective, single center, observational study.
    D'Erasmo L; Commodari D; Di Costanzo A; Minicocci I; Polito L; Ceci F; Montali A; Maranghi M; Arca M
    Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):2027-2035. PubMed ID: 32830020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia.
    Brandts J; Dharmayat KI; Vallejo-Vaz AJ; Azar Sharabiani MT; Jones R; Kastelein JJP; Raal FJ; Ray KK
    Atherosclerosis; 2021 May; 325():46-56. PubMed ID: 33901739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heterozygous familial hypercholesterolemia: prevalence and control rates.
    Polychronopoulos G; Tzavelas M; Tziomalos K
    Expert Rev Endocrinol Metab; 2021 Jul; 16(4):175-179. PubMed ID: 33993819
    [No Abstract]   [Full Text] [Related]  

  • 27. [PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement].
    Soška V; Vrablík M; Bláha V; Cífková R; Češka R; Freiberger T; Kraml P; Piťha J; Rosolová H; Štulc T; Vaverková H; Urbanová Z
    Vnitr Lek; 2016 Apr; 62(4):329-33. PubMed ID: 27250613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
    Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P
    J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia.
    Bea AM; Perez-Calahorra S; Marco-Benedi V; Lamiquiz-Moneo I; Jarauta E; Mateo-Gallego R; Civeira F
    Atherosclerosis; 2017 Aug; 263():92-96. PubMed ID: 28623742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.
    El Khoury P; Elbitar S; Ghaleb Y; Khalil YA; Varret M; Boileau C; Abifadel M
    Curr Atheroscler Rep; 2017 Oct; 19(12):49. PubMed ID: 29038906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study.
    Daniels S; Caprio S; Chaudhari U; Manvelian G; Baccara-Dinet MT; Brunet A; Scemama M; Loizeau V; Bruckert E
    J Clin Lipidol; 2020; 14(3):322-330.e5. PubMed ID: 32331936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment of heterozygous familial hypercholesterolemia - a local perspective.
    Bułdak Ł
    Endokrynol Pol; 2021; 72(3):189-190. PubMed ID: 34292576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
    Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L
    Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry.
    Béliard S; Boccara F; Cariou B; Carrié A; Collet X; Farnier M; Ferrières J; Krempf M; Peretti N; Rabès JP; Varret M; Vimont A; Charrière S; Bruckert E;
    Atherosclerosis; 2018 Oct; 277():334-340. PubMed ID: 30270068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCSK9 antibodies for the treatment of hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Nutrients; 2014 Dec; 6(12):5517-33. PubMed ID: 25470376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
    Hovingh GK; Raal FJ; Dent R; Stefanutti C; Descamps O; Masana L; Lira A; Bridges I; Coll B; Sullivan D
    J Clin Lipidol; 2017; 11(6):1448-1457. PubMed ID: 29066265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PCSK9 antibodies: A new class of lipid-lowering drugs.
    Gouni-Berthold I
    Atheroscler Suppl; 2015 May; 18():21-7. PubMed ID: 25936300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.
    Catapano AL; Pirillo A; Norata GD
    Vasc Health Risk Manag; 2017; 13():343-351. PubMed ID: 28919772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evolocumab: A Review in Hyperlipidemia.
    Keating GM
    Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.